

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
29 December 2016 (29.12.2016)



(10) International Publication Number
WO 2016/209555 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/506 (2006.01)
A61K 31/165 (2006.01) A61K 47/30 (2006.01)
A61K 31/416 (2006.01)

(21) International Application Number:

PCT/US2016/034822

(22) International Filing Date:

27 May 2016 (27.05.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/183,180 22 June 2015 (22.06.2015) US

(71) Applicant: ALLGENESIS BIOTHERAPEUTICS INC.;
7F.-1, No. 760, Sec. 4, Bade Road, Songshan District,
Taipei City, 105 (TW).

(72) Inventor; and

(71) Applicant (for US only): NGUYEN, Tan [US/US]; 3117
Lantana Avaneue, Fullerton, CA 92835 (US).

(72) Inventor: LAI, Chin-yu; 7F.-1, No. 760, Sec. 4, Bade
Road, Songshan District, Taipei City, 105 (TW).

(74) Agents: SHANAHAN, Carly, A. et al.; Panitch Schwarze
Belisario & Nadel LLP, One Commerce Square, 2005 Mar-
ket Street, Suite 2200, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHODS OF USE THEREOF, AND
PREPARATION METHODS THEREOF

Fig. 6



(57) Abstract: Ophthalmic formulations containing tyrosine kinase inhibitors, such as Nintedanib, Axitinib, Sorafenib, and Pazo-
panib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. Also
described are methods of using the ophthalmic formulations for treating ocular surface diseases, such pterygium, including recurrent
pterygium, and hyperemia associated with pterygium.

WO 2016/209555 A1